When is the deadline for CIMG to achieve compliance and what steps are being taken to address the issue?

Compliance deadline & remediation plan

Nasdaq’s notice gives CIMG Inc. (Nasdaq: IMG) 30 calendar days to cure the listing deficiencies – the window closes September 30 2025. The company has already launched a multi‑prong remediation effort: it is working with a specialist compliance‑consulting firm to complete the overdue periodic filings, tightening its corporate‑governance controls, and allocating additional internal resources (including a dedicated “Nasdaq compliance officer”) to monitor and report on the required metrics. CIMG also plans to submit a detailed compliance‑re‑qualification package to Nasdaq by the end of the 30‑day period, covering both the immediate filing shortfalls and a longer‑term governance overhaul.

Trading implications

The 30‑day compliance window introduces a clear, time‑bounded catalyst. If Nasdaq confirms that the cure‑plan is satisfactory before the September 30 deadline, the regulatory risk premium is likely stripped away, prompting a bounce‑back in the stock – historically a 10‑15 % rally for similar small‑cap de‑listings that are resolved. Conversely, any further delay or a rejection of the cure package could trigger a sharp sell‑off, as market participants price in the probability of delisting, loss of liquidity, and possible forced restructuring. From a technical standpoint, the price is currently testing the lower trend‑line of a descending channel that began in early 2025; a decisive move above the recent high (~$3.10) would confirm a short‑term reversal, while a break below the lower support (~$2.70) would signal heightened downside pressure.

Actionable outlook

• Long‑biased if Nasdaq acknowledges compliance by early‑mid September – consider buying on any bounce‑back and targeting $3.30‑$3.50 as the next resistance level (previous high in May 2025).
  
• Short‑biased if filing gaps persist or Nasdaq issues a non‑compliance extension – protect upside with a stop‑loss around $3.00 and look to capture a move toward $2.60‑$2.40, reflecting delisting‑risk premium.
  

Overall, the September 30 deadline is the key inflection point; monitor Nasdaq’s correspondence flow and any corporate updates on the cure‑plan execution before taking a definitive position.